MeiraGTx Holdings Plc (MGTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MeiraGTx Holdings Plc (MGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8157
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The company’s pipeline of preclinical and research programs include AAV-CNGB3, for achromatopsia; AAV-RPGR, for X-linked retinitis pigmentosa; AAV-RPE65, for RPE65-Deficiency; AAV-AQP1, for xerostomia and sjogren’s syndrome; and AAV-UPF1, for amyotrophic lateral sclerosis (ALS) among others. MeiraGTx works in collaboration with leading institutions to develop next-generation gene therapies. The company has presence in the US, the UK and the Netherlands. MeiraGTx is headquartered in New York, the US.

MeiraGTx Holdings Plc (MGTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 10
MeiraGTx and eXmoor pharma Enter into Agreement 11
Oxford Genetics Enters into Agreement with MeiraGTx 12
MeiraGTx Enters into Agreement with Weill Cornell Medicine 13
MeiraGTx Enters into Agreement with Weill Cornell Medicine and LSU Health Shreveport 14
Athena Vision Enters into Agreement with MeiraGTx 15
Licensing Agreements 16
MeiraGTx Enters into Licensing Agreement with UCL Business 16
MeiraGTx Enters into Licensing Agreement with UCL Business 17
Equity Offering 18
MeiraGTx Raises USD75 Million in IPO of Shares 18
Acquisition 19
MeiraGTx Acquires Vector Neurosciences 19
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 20
MeiraGTx Holdings Plc – Key Competitors 21
MeiraGTx Holdings Plc – Key Employees 22
MeiraGTx Holdings Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Legal and Regulatory 24
Jun 21, 2018: MeiraGTx Announces MHRA Grants MIA (IMP) License for cGMP Manufacturing Facility in London, UK 24
Government and Public Interest 25
Feb 01, 2017: MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS 25
Product News 26
08/24/2017: MeiraGTx Provides Clinical Trial Update for Leber Congenital Amaurosis Type 2 Gene Therapy Program 26
Product Approvals 27
Dec 07, 2017: MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Leber’s Congenital Amaurosis and Treats First Pediatric Patient in Phase I/II Clinical Trial 27
Clinical Trials 28
Oct 17, 2017: MeiraGTx Presents Preclinical Data on AAV2/5-OPTIRPE65 for the Treatment of Lebers Congenital Amaurosis at ESGCT 2017 Congress in Berlin 28
Aug 24, 2017: MeiraGTx Provides Clinical Trial Update for Achromatopsia Gene Therapy Program 29
Aug 24, 2017: MeiraGTx Provides Clinical Trial Update for X-Linked Retinitis Pigmentosa Gene Therapy Program 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MeiraGTx Holdings Plc, Deals By Therapy Area, 2012 to YTD 2018 8
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 10
MeiraGTx and eXmoor pharma Enter into Agreement 11
Oxford Genetics Enters into Agreement with MeiraGTx 12
MeiraGTx Enters into Agreement with Weill Cornell Medicine 13
MeiraGTx Enters into Agreement with Weill Cornell Medicine and LSU Health Shreveport 14
Athena Vision Enters into Agreement with MeiraGTx 15
MeiraGTx Enters into Licensing Agreement with UCL Business 16
MeiraGTx Enters into Licensing Agreement with UCL Business 17
MeiraGTx Raises USD75 Million in IPO of Shares 18
MeiraGTx Acquires Vector Neurosciences 19
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 20
MeiraGTx Holdings Plc, Key Competitors 21
MeiraGTx Holdings Plc, Key Employees 22
MeiraGTx Holdings Plc, Subsidiaries 23

List of Figures
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[MeiraGTx Holdings Plc (MGTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genel Energy Plc (GENL):石油・ガス:M&Aディール及び事業提携情報
    Summary Genel Energy Plc (Genel) is an independent upstream oil and gas company. It carries out acquisition, exploration, and production operations. It has interest in Taq Taq and Tawke in the Kurdistan region. The company develops the Miran and Bina Bawi gas fields in Zagros Fold belt in the Kurdis …
  • Hwa Tai Industries Berhad:企業の戦略・SWOT・財務分析
    Hwa Tai Industries Berhad - Strategy, SWOT and Corporate Finance Report Summary Hwa Tai Industries Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • 99 Cents Only Stores LLC:企業の戦略的SWOT分析
    99 Cents Only Stores LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Enstar Group Ltd.:企業のM&A・事業提携・投資動向
    Enstar Group Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Enstar Group Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Prologis Inc (PLD):企業の財務・戦略的SWOT分析
    Prologis Inc (PLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Seylan Bank Plc:企業の戦略・SWOT・財務情報
    Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ultra Petroleum Corp (UPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Ultra Petroleum Corp (Ultra) is an independent upstream company, which develops, produces, operates, explores, and acquires oil and natural gas properties. It develops long-life natural gas reserves in the Green River Basin of Wyoming, the Pinedale and Jonah fields, and oil reserves in the U …
  • Huron Consulting Group Inc
    Huron Consulting Group Inc - Strategy, SWOT and Corporate Finance Report Summary Huron Consulting Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Galp Energia SGPS SA (GALP):石油・ガス:M&Aディール及び事業提携情報
    Summary Galp Energia SGPS SA (Galp) is an integrated energy company. It explores for, develops and produces crude oil and natural gas, refines crude oil, and markets refined petroleum products. The company also conducts power generation, produces biodiesel and trades gas. It imports, transports and …
  • Warisan TC Holdings Berhad:企業の戦略・SWOT・財務情報
    Warisan TC Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Warisan TC Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • ENN Energy Holdings Ltd (2688):企業の財務・戦略的SWOT分析
    ENN Energy Holdings Ltd (2688) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Eletrosul Centrais Eletricas SA:電力:M&Aディール及び事業提携情報
    Summary Eletrosul Centrais Eletricas SA (Eletrosul) is a power generation company. The company’s business activities include generation, transmission, commercialization of energy and telecommunication services. It also invests in research and development of alternative energy sources. Eletrosul’s ge …
  • Lockheed Martin Aeronautics Company:企業の戦略・SWOT・財務分析
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Generex Biotechnology Corp (GNBT):医療機器:M&Aディール及び事業提携情報
    Summary Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulatio …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Shree Renuka Sugars Ltd (RENUKA):企業の財務・戦略的SWOT分析
    Shree Renuka Sugars Ltd (RENUKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Euler Hermes SA:企業の戦略・SWOT・財務情報
    Euler Hermes SA - Strategy, SWOT and Corporate Finance Report Summary Euler Hermes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • 84 Lumber Company:企業の戦略・SWOT・財務情報
    84 Lumber Company - Strategy, SWOT and Corporate Finance Report Summary 84 Lumber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Apotex, Inc.:企業の戦略・SWOT・財務情報
    Apotex, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apotex, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Rafael Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rafael Pharmaceuticals Inc (Rafael Pharmaceuticals), a subsidiary of IDT Corp is a healthcare products provider that offers therapeutics. The company develops drug therapies for the treatment of cancer. It provides altered energy metabolism directed platform for cancer cell energy metabolism …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆